Investigators are halting recruitment for a small study using T cells reengineered with chimeric antigen receptors against CD19-positive B cells for aggressive non-Hodgkin lymphoma, triggering concerns about the potential fallout at Juno Therapeutics, the biotech formed to commercialize the effort.

…read more

Source: UPDATED: Memorial Sloan-Kettering hits the brakes on engineered T cell cancer study


0 No comments